 |
|
|
REFERENCES
1.
Laurent JF, Richter F, Michel A: Management of
victims of urban chemical attack: The French approach. Resuscitation 42:141, 1999.
2.
Okumura T, Suzuki K, Fukada A, et al: The Tokyo
subway sarin attack: Disaster management. Part 2. Hospital response. Acad Emerg
Med 5:618, 1998.
3.
Hobbiger F: The pharmacology of anticholinesterase
drugs. In Handbook of Experimental Pharmacology,
vol 42. The Neuromuscular Junction. Berlin, Springer-Verlag, 1976.
4.
Koelle G (ed): Handbook of Experimental Pharmacology,
vol 15. Cholinesterase and Anticholinesterase Agents. Berlin, Springer-Verlag,
1963.
5.
White SM: Chemical and biological weapons: Implications
for anaesthetic and intensive care. Br J Anaesth 89:306, 2002.
6.
Somani S (ed): Chemical Warfare Agents. San Diego,
Academic Press, 1992.
7.
Marrs TC, Maynard RL, Sidell FR (eds): Chemical
Warfare Agents: Toxicology and Treatment. Chichester, UK, John Wiley & Sons,
1996.
8.
Baker DJ, Rustick JM: Anesthesia for casualties
of chemical warfare agents. In Zaitchuk R, Grande
C (eds): US Army Textbook of Military Medicine, part IV, vol 1. Washington, DC,
US Department of the Army, 1995.
9.
Baker DJ: Anesthesia in extreme environmental conditions.
Part 2. Chemical and biologic warfare. In Grande
CG (ed): Textbook of Trauma Anesthesia and Critical Care. Baltimore, Mosby-Year
Book, 1993, pp 1320–1354.
10.
Christopher GW, Sieslak TJ, Parlin JA, Eitsen EM:
Biological warfare: A historical perspective. JAMA 278:412, 1997.
11.
Franz DR, Jahrburg PB, Friedlander AM, et al:
Clinical recognition and management of patients exposed to biological warfare agents.
JAMA 278:399, 1997.
12.
Zaitchuk R (ed): Medical aspects of chemical and
biological warfare chemical warfare. US Army Textbook of Military Medicine, part
1, vol 5. Washington, DC, US Department of the Army, 1997.
13.
Harris R, Paxman J: A higher form of killing.
London, Chatto & Windus, 1982.
14.
Stockholm International Peace Research Institute:
The problem of Chemical and Biological Warfare. The Rise of CBW Weapons, vol 1.
Stockholm, SIPRI, 1971.
15.
Alibek K: Biohazard. London, Arrow Books, 1999.
16.
Zilinskas RA: Verifying compliance to the biological
and toxin weapons convention. Crit Rev Microbiol 24:195, 1998.
17.
Ministry of Defence: Medical Manual of Defence
Against Chemical Agents, D/Med (F and S)(2)/10/1/1 p1-1. London, Her Majesty's Stationery
Office, 1987.
18.
Baker DJ: Chemical and biological warfare agents:
A fresh approach. Janes Intell Rev 5(1):42, 1993.
19.
Bronstein AC, Currance PL: Emergency Care for
Hazardous Materials Exposure, 2nd ed. St. Louis, Mosby Lifeline, 1994.
20.
Borak J, Callan M, Abbott W: Hazardous materials
exposure: Emergency response and patient care. Englewood Cliffs, NJ, Prentice Hall,
1991.
21.
Gilchrist HL: Statistical consideration of gas
casualties. In Weed FW, Ireland MW (eds): Medical
Aspects of Gas Warfare, vol 14. The Medical Department of the United States Army
in the World War. Washington, DC, Governmment Printing Office, 1926.
22.
Hemsley J, Royal United Services Institute. The
Soviet Biochemical Threat to NATO. London, Macmillan, 1987.
23.
United Nations: Report of the mission dispatched
by the Secretary General to investigate allegations of the use of chemical weapons
in the conflict between the Islamic Republics of Iran and Iraq. UN document no.
18852. New York, United Nations, 1987.
24.
Tu AT: Overview of the sarin terrorist incidents
in Japan in 1994 and 1995. In Proceedings of the
6th BCW Protective Symposium, Stockholm, NDRE FOR-R-98, 00949-862-6E. Umea, Sweden,
Defence Research Establishment, 1998.
25.
Okumura T, Suzuki K, Fukada A, et al: The Tokyo
subway sarin attack: Disaster management. Part 2. Hospital response. Acad Emerg
Med 5:618, 1998.
26.
Dhara VR, Dhara K: The Union Carbide disaster
in Bhopal: A review of health effects. Arch Environ Health 57:391, 2002.
27.
Marrs TC: Organophosphates: History, chemistry,
pharmacology. In Laralliedde L, Feldman, S, Henry
J, Marrs TC (eds): Organophosphates and Health. London, Imperial College Press,
2001.
28.
Kato T, Hamanaka T: Ocular signs and symptoms
caused by exposure to sarin gas. Am J Opthalmol 121:209, 1996.
29.
Rickett DI, Glenn JF, Beers ET: Central respiratory
effects versus neuromuscular actions of nerve agents. Neurotoxicology 7:225, 1986.
30.
Saadeh AM, Farsakh NA, Al-Ali MK: Cardiac manifestations
of acute carbamate and organophosphate poisoning. Heart 77:461, 1997.
31.
Wang MH, Tseng CD, Blair SY: Q-T interval prolongation
and pleomorphic ventricular tachyarrhythmias (torsade de pointes) in organophosphorus
poisoning: Report of a case. Hum Exp Toxicol 17:587, 1998.
32.
Chuang FR, Jang SW Lin JL, et al: Q-Tc prolongation
indicates a poor prognosis in patients with organophosphate poisoning. Am J Emerg
Med 14:451, 1996.
33.
Kadivar H, Adams SC: Treatment of chemical and
biological warfare injuries: Insights gained from the 1984 Iraqi attack on Majnoon
Island. Mil Med 156:171, 1991.
34.
Hammick M: All stick and no carrot. Int Defense
Rev Dec:1323, 1991.
35.
Murray V, Minton NA: A review of organophosphate
poisoning. Med Toxicol Adverse Drug Exp 3:350, 1988.
36.
Ram JS, Kumar SS, Kuppuswamy G: Continuous infusion
of high doses of atropine in the management of organophosphorus compound poisoning.
J Assoc Physicians India 39:190, 1991.
37.
Dawson RM: Review of oximes available for nerve
agent poisoning. J Appl Toxicol 14:317, 1994.
38.
Worek F, Backer M, Thiermann H, et al: Reappraisal
of indications and limitations of oxime therapy in organophosphate poisoning. Hum
Exp Toxicol 16:466, 1997.
39.
Inns RH, Leadbeater L: The efficacy of bispyridinium
compounds in the treatment of organophosphate poisoning in the guinea pig. J Pharm
Pharmacol 5:427, 1983.
40.
Worek F, Eyer P, Kiderlen D, et al: Effect of
human plasma on the reactivation of sarin-inhibited human erythrocyte acetylcholinesterase.
Arch Toxicol 74:21, 2000.
41.
Holstege CP, Kirk M, Sidell FR: Chemical warfare:
Nerve agent poisoning. Crit Care Clin 13:923, 1997.
42.
McDonough JH Jr, Zoeffel LD, McMonagle J, et al:
Anticonvulsant treatment of nerve agent seizures: Anticholinergics versus diazepam
in soman-intoxicated guinea pigs. Epilepsy Res 38:1, 2000.
43.
Keeler JR, Hurst CG, Dunn MA: Pyridostigmine used
as a nerve agent pretreatment under wartime conditions. JAMA 266:694, 1991.
44.
Pellegrini JE, Baker AB, Fontenot DJ, Cardenas
AF: The effect of oral pyridostigmine bromide nerve agent prophylaxis on return
of twitch height in persons receiving succinyl choline. Mil Med 165:252, 2000.
45.
Turner GA, Williams JD, Baker DJ: Effect of pretreatment
with oral pyridostigmine on subsequent activity of alcuronium in non-anaesthetized
subjects. Br J Anaesth 66:365, 1991.
46.
Ali HH, Savarese JJ: Monitoring of neuromuscular
function. Anesthesiology 45:216, 1975.
47.
Bowman WC: Prejunctional and postjunctional cholinoceptors
at the neuromuscular junction. Anesth Analg 59:935, 1980.
48.
Sidell FR, Hurst CG: Clinical considerations in
mustard poisoning. In Somani S (ed): Chemical Warfare
Agents. San Diego, Academic Press, 1992.
49.
Willems JL: Clinical management of mustard gas
casualties. Ann Med Mil Belg 3(Suppl):1, 1989.
50.
United Nations: Report of the mission dispatched
by the Secretary-General to investigate allegations of the use of chemical weapons
in the conflict between Iran and Iraq. UN Document S/17911. New York, United Nations,
1986.
51.
Urbanetti JS: Toxic inhalation injury. In
Zajchuk R (ed): Textbook of Military Medicine part 1, vol 5. Medical Aspects of
Chemical and Biological Warfare. Washington, DC, US Department of the Army, 1997.
52.
Borak MD, Sidell F: Agents of chemical warfare:
Sulfur mustard. Ann Emerg Med 21:308, 1992.
53.
Colardyn F, de Keyser H, Ringoir S, de Bersaques
J: Clinical observations and therapy of injuries with vesicants. J Toxicol Clin
Exp 6:237, 1986.
54.
Varma DR, Guest I: The Bhopal incident and methyl
isocyanate toxicity. J Toxicol Environ Health 40:513, 1993.
55.
Mehta PS, Mehta AS, Mehta SJ, Makhijani AB: Bhopal
tragedy's health effects: A review of methyl isocyanate toxicity. JAMA 264:2781,
1990.
56.
Marrs TC, Maynard RL, Sidell FR (eds): Phosgene.
In Chemical Warfare Agents: Toxicology and Treatment.
Chichester, UK, John Wiley & Sons, 1995.
57.
Diller WF: Medical phosgene problems and their
possible solution. Occup Med 20:189, 1978.
58.
Agency for Toxic Substances and Disease Registry
(ATSDR). Available at www.atsdr.cdc.gov/Accessed 2003.
59.
Papadakos P, Lachmann B: The open lung concept
of alveolar recruitment can improve outcome in respiratory failure and ARDS. Mt
Sinai J Med 69:73, 2002.
60.
Lachman B: The concept of open lung management.
Int J Intensive Care 7:215, 2000.
61.
Diller WF: Therapeutic strategy in phosgene poisoning.
Toxicol Ind Health 1:93, 1985.
62.
Gunnarsson M, Walther SM, Seidal T, Lennquist S:
Effects of inhalation of corticosteroids immediately after experimental chlorine
gas lung injury. J Trauma 48:101, 2000.
63.
Wang J, Zhang L, Walther SM: Inhaled budesonide
in experimental chlorine gas chlorine gas injury: Influence of time interval between
injury and treatment. Intensive Care Med 28:352, 2002.
64.
Demnati R, Fraser R, Martin JG, et al: Effects
of dexamethasone on functional and pathological changes in rat bronchi caused by
high acute exposure to chlorine. Toxicol Sci 45:242, 1998.
65.
Kennedy TP, Michael JR, Hoidal JR, et al: Dibutaryl
cAMP, aminophylline and beta-adrenergic agonists protect against pulmonary oedema
caused by phosgene. J Appl Physiol 67:2542, 1989.
66.
Sciuto AM, Strickland PT, Kennedy TP, Gurtner GH:
Protective effects of N-acetyl cysteine treatment
after phosgene exposure in rabbits. Am J Respir Crit Care Med 151:768, 1995.
67.
Anderson DR, Byers SL, Vesely KR: Treatment of
sulfur mustard (HD)-induced lung injury. J Appl Toxicol 20:S129, 2000.
68.
Baskin SI, Brewer TG: Cyanide poisoning. In
Zaichuk R (ed): Textbook of Military Medicine and Biological Warfare. Washington,
DC, US Department of the Army, 1997, p 271.
69.
Meredith TJ, Jacobsen D, Haines JA, et al (eds):
IPCS/CEC Evaluation of Antidote Series, vol 2. Antidotes for Poisoning by Cyanide.
Cambridge, UK, Cambridge University Press, 1993 (http://www.inchem.org/documents/antidote/antidote/ant02.htm).
70.
Beasley DMG, Glass WI: Cyanide poisoning: Pathophysiology
and treatment recommendations. Occup Med 48:427, 1998.
71.
Baskin SI, Horowitz AM, Nealley EW: The antidotal
action of sodium nitrite and sodium thiosulfate against cyanide poisoning. J Clin
Pharmacol 32:368, 1992.
72.
Way JL: Cyanide intoxication and its mechanism
of antagonism. Annu Rev Pharmacol Toxicol 24:451, 1984.
73.
Karalliedde L: Animal toxins. Br J Anaesth 74:319,
1995.
74.
Franz DR: International Biological Warfare Threat
in CONUS. Statement before the Joint Committee on Judiciary and Intelligence, US
Senate, March 4, 1998 (http://judiciary.Senate.gov/oldsite/franz.html).
75.
Arnon S, Schechter R, Inglesby T, et al: Botulinum
toxin as a biological weapon. JAMA 285:1059, 2001.
76.
Stalberg E, Trontlj JV: Single Fiber Electromyography:
Studies in Healthy and Diseased Muscle, 2nd ed. New York, Raven Press, 1994.
77.
Lederberg J (ed): Biological Weapons: Limiting
the Threat. London, MIT Press, 1999.
78.
Watters MR: Organic neurotoxins in seafoods.
Clin Neurol Neurosurg 97:119, 1995.
79.
Benton BJ, Rivera VR, Hewetson JF, Chang FC: Reversal
of saxitoxin-induced cardiorespiratory failure by a burro-raised alpha-STX antibody
and oxygen therapy. Toxicol Appl Pharmacol 124:39, 1994.
80.
Lemley PV, Thalley BS, Stafford DC: Prophylactic
and therapeutic efficacy of an avian antitoxin in ricin intoxication. Ther Immunol
2:59, 1995.
81.
Leppla SH: Anthrax toxin edema factor: A bacterial
adenylate cyclase that increases cyclic AMP concentrations in eukaryotic cells.
Proc Natl Acad Sci U S A 79:3162, 1982.
82.
O'Brien J, Friedlander A, Dreier T, et al: Effects
of anthrax toxin components on human neutrophils. Infect Immunol 47:3016, 1985.
83.
Centers for Disease Control and Prevention: Bioterrorism
alleging use of anthrax and interim guidelines for management. MMWR Morb Mortal
Wkly Rep 48:69, 1999.
84.
Butler T: Yersina species including plague. In
Mandell GL, Bennett JE, Dolin R (eds): Principles and Practice of Infectious Diseases,
5th ed. Philadelphia, Churchill Livingstone, 2000, p 2406.
85.
McGovern TW, Friedlander AM: Plague. In
Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare.
Washington, DC, US Department of the Army, 1997, p 479.
86.
Carpenter CCJ: Cholera. In
Weatherall DJ, Ledingham JGG, Warrell DA (eds): Oxford Textbook of Medicine, 2nd
ed. Oxford, UK, Oxford University Press, 1987, p 231.
87.
Centers for Disease Control and Prevention: Laboratory
acquired human glanders—Maryland. MMWR Morb Mortal Wkly Rep 49:532, 2000.
88.
McGovern TW, Christopher GW, Eitsen EM: Cutaneous
manifestations of biological warfare and related threat agents. Arch Dermatol 135:311,
1999.
89.
Moles TM: Emergency medical services systems and
HAZMAT major incidents. Resuscitation 42:103, 1999.
90.
Baker DJ: Management of respiratory failure in
toxic disasters. Resuscitation 42:125, 1999.
91.
de Bleeker JL: The Intermediate Syndrome in organophosphate
poisoning: An overview of experimental and clinical observations. J Toxicol Clin
Toxicol 33:683, 1995.
